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Abstract
Introduction Once metastasis has occurred, the possibility of
completely curing breast cancer is unlikely, particularly for the
30 to 40% of cancers overexpressing the gene for HER2/neu.
A vaccine targeting p185, the protein product of the HER2/neu
gene, could have therapeutic application by controlling the
growth and metastasis of highly aggressive HER2/neu+ cells.
The purpose of this study was to determine the effectiveness of
two gene vaccines targeting HER2/neu  in preventive and
therapeutic tumor models.
Methods The mouse breast cancer cell line A2L2, which
expresses the gene for rat HER2/neu and hence p185, was
injected into the mammary fat pad of mice as a model of solid
tumor growth or was injected intravenously as a model of lung
metastasis. SINCP-neu, a plasmid containing Sindbis virus
genes and the gene for rat HER2/neu, and Adeno-neu, an
E1,E2a-deleted adenovirus also containing the gene for rat
HER2/neu, were tested as preventive and therapeutic vaccines.
Results Vaccination with SINCP-neu  or Adeno-neu  before
tumor challenge with A2L2 cells significantly inhibited the
growth of the cells injected into the mammary fat or
intravenously. Vaccination 2 days after tumor challenge with
either vaccine was ineffective in both tumor models. However,
therapeutic vaccination in a prime–boost protocol with SINCP-
neu followed by Adeno-neu significantly prolonged the overall
survival rate of mice injected intravenously with the tumor cells.
Naive mice vaccinated using the same prime–boost protocol
demonstrated a strong serum immunoglobulin G response and
p185-specific cellular immunity, as shown by the results of
ELISPOT (enzyme-linked immunospot) analysis for IFNγ .
Conclusion We report herein that vaccination of mice with a
plasmid gene vaccine and an adenovirus gene vaccine, each
containing the gene for HER2/neu, prevented growth of a
HER2/neu-expressing breast cancer cell line injected into the
mammary fat pad or intravenously. Sequential administration of
the vaccines in a prime–boost protocol was therapeutically
effective when tumor cells were injected intravenously before
the vaccination. The vaccines induced high levels of both
cellular and humoral immunity as determined by in vitro
assessment. These findings indicate that clinical evaluation of
these vaccines, particularly when used sequentially in a prime–
boost protocol, is justified.
Introduction
Once metastasis has occurred, the possibility of completely
curing breast cancer is unlikely [1], particularly for the 30 to
40% of cancers overexpressing the gene for HER2/neu [2]. A
vaccine targeting HER2/neu could have considerable preven-
tive and therapeutic application by controlling the growth and
metastasis of highly aggressive HER2/neu+ tumor cells [3,4].
Gene vaccines, which are bacterial expression plasmids
encoding the DNA sequence for tumor antigens, have induced
strong antitumor immunity in animals [5]. Although gene
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vaccines have shown effectiveness in clinical trials [6-13], only
a few trials have been completed in oncology patients, and the
results have been mixed [14-19]. However, it was recently
demonstrated that a gene vaccine for prostate-specific anti-
gen broke immunologic tolerance and induced cellular immu-
nity [20]. Immunotherapy for cancer using gene vaccines is in
its infancy, and the development of new approaches and tech-
niques is anticipated [21-24].
The fields of gene therapy and gene vaccines have recently
converged, as shown by the use of identical delivery systems
for both purposes [25]. Alphaviruses such as the Sindbis,
Semliki Forest, and Venezuelan equine encephalitis viruses
may be used for both gene therapy and gene vaccines [26-
28]. We [29] and others [30] have shown that plasmids con-
taining Sindbis virus genes induce excellent antitumor immu-
nity in murine tumor models. Adenoviruses, the workhorse of
gene replacement therapy, are quickly moving to the forefront
as gene vaccine vectors [31-35]. Unlike alphaviruses, which
contain self-replicating RNA [36], adenoviruses contain DNA
as their genetic material. For both families of viruses, essential
genes for replication or packaging are deleted or mutated to
ensure the safety of the gene therapy or gene vaccine vector.
Although animal models of tumor growth are limited in their
ability to represent clinical cancer, models can provide valua-
ble information about drug candidates. We have used both
preventive and therapeutic murine tumor models to evaluate
the effectiveness of two gene vaccines. Our results demon-
strated that each gene vaccine was effective in prevention
models, but neither was effective when used in a therapeutic
model. However, prime–boost vaccination with SINCP-neu
followed by Adeno-neu significantly prolonged the overall sur-
vival rate when used therapeutically in a murine model of
breast cancer metastasis. This finding indicates that effective
vaccine immunotherapy may require treatment with at least
two gene vaccines delivered in a precise order.
Materials and methods
Tumor cell line and reagents
The A2L2 cell line, which expresses high levels of rat HER2/
neu, was derived from the mouse tumor cell line 66.3 in our
laboratory [29]. The A2L2 cell line has expressed high levels
of HER2/neu for more than 5 years and consistently induces
tumors in BALB/c mice when injected into a mammary fat pad
or intravenously (i.v.). The line was maintained in Eagle's mini-
mal essential medium containing 5% fetal bovine serum,
sodium pyruvate, nonessential amino acids, L-glutamine, and
vitamins (Gibco, Carlsbad, CA, USA). The monolayer cultures
were subdivided at approximately 75% confluence by treat-
ment for 1 to 3 min with 0.25% trypsin and 0.02% ethylenedi-
aminetetraacetic acid (EDTA) at 37°C.
SINCP-neu and Adeno-neu gene vaccines
The SINCP plasmid, which contains Sindbis virus genes, was
provided by Dr John Polo (Chiron, Emeryville, CA, USA).
SINCP is nearly identical to the ELVIS plasmid we previously
tested [29] except for an internal ribosome entry site on the 5'
side of the insertion point for an antigen gene. The gene for rat
neu was excised from pSV2-neu and inserted into SINCP by
standard recombinant DNA techniques [29]. The correct
insertion of the complete neu  gene was confirmed by
sequence analysis. The E1,E2a-deleted adenovirus (Adeno)
has been described in detail [37,38]. The gene for rat neu was
excised from pSV2-neu and incorporated into Adeno as previ-
ously described [38].
Flow cytometric analysis
To evaluate the level of immunoglobulin G (IgG) in the serum
of vaccinated mice, we incubated A2L2 cells for 1 hour at
37°C with either immune serum or control serum diluted
1:100 in PBS, pH 7.2. Fluorescein-isothiocyanate-labeled
(FITC-labeled) goat antimouse IgG (Pharmingen, San Diego,
CA, USA) diluted 1:1000 in PBS was added to the cells, and
incubation continued for 1 hour at 37°C. The cells were
washed three times in PBS and analyzed by flow cytometry
using an EPICS Profile Analyzer (Coulter, Hialeah, FL, USA).
As a positive control, A2L2 cells were stained with a 1:1000
dilution of a polyclonal rabbit antibody against p185 (sc-284;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) and an
FITC-labeled goat anti-rabbit IgG.
Mice
Female BALB/c mice 6 to 8 weeks old were obtained from the
National Cancer Institute-Frederick Cancer Research Facility
(Frederick, MD, USA). Mice were acclimated for at least 1
week before use. Our small-animal facility is approved by the
Association for the Assessment and Accreditation of Labora-
tory Animal Care (AAALAC).
Vaccination of mice with SINCP-neu and Adeno-neu
SINCP-neu was prepared in milligram quantities by Aldevron
(Fargo, ND, USA). Intramuscular (i.m.) injections of 0.1 ml con-
taining 100 µg of plasmid DNA formulated with 0.25% bupi-
vacaine (Sigma Chemical, St Louis, MO, USA) were
administered to the quadriceps using a 24-gauge needle.
Adeno-neu and adenovirus lacking an inserted gene (Adeno-
empty) were suspended in 100 µl of 0.85% saline and
injected into the quadriceps using a 24-gauge needle. Blood
was collected at intervals from the tail vein, and the serum was
separated by centrifugation after incubation at 37°C for 1 hour
and overnight refrigeration.
Mammary fat pad tumor prevention model
We used a mammary fat pad tumor prevention model to
assess the effect of vaccination on solid tumor development.
A2L2 cells from cultures that had reached 75% confluence
were harvested by treatment with 0.25% trypsin and 0.02%Available online http://breast-cancer-research.com/content/7/5/R580
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EDTA for 1 to 3 min at 37°C. The cells were washed once in
serum-containing culture medium and once in PBS. Mice were
anesthetized by inhalation of isoflurane using an apparatus
developed by veterinarians at the University of Texas MD
Anderson Cancer Center [39]. The fur was shaved over the
lateral thorax, and a 5-mm-long incision was made to reveal
mammary fat pad number 2 [40]. A 0.1-ml sample containing
2.5 × 104 A2L2 cells in normal saline was injected into the fat
pad. The incision was closed with a wound clip. After 7 days,
wound clips that had not already fallen off were removed. The
mice were then observed daily, and their tumors were meas-
ured in perpendicular directions using a caliper. Mice with
tumors at least 10 mm in the greater dimension were killed
according to our approved Institutional Animal Care and Use
protocol. At the end of the experiment, all mice were killed by
CO2 inhalation, and all tumors were excised and weighed.
Examination of the surface of the lungs during necropsy did
not reveal tumor nodules.
Experimental metastasis prevention model
Although a solid tumor develops after injection of A2L2 cells
into the mammary fat pad, it is not highly metastatic. The tumor
induces moribundity in mice before an appreciable number of
lung metastases develop. For this reason, we used an experi-
mental lung metastasis model rather than a spontaneous lung
metastasis model to assess the effect of vaccination on lung
metastasis. A 0.1-ml sample containing 2.5 × 104 A2L2 cells
in normal saline was injected into the tail vein of each immu-
nized mouse. Thirty days later, the mice were killed by CO2
inhalation, and surface lung metastases in each animal were
counted.
ELISPOT analysis of IFNγ  production by immune spleen 
cells
To determine the number of interferon-γ -producing (IFNγ -pro-
ducing) cells in the spleens of vaccinated mice, we used an
IFNγ  enzyme-linked immunospot (ELISPOT) technique (kit no.
552569; Pharmingen) and used reagents from Pharmingen
whenever possible. Immune spleens were dissected from vac-
cinated mice and prepared exactly as previously described for
tetramer analysis [41]. Wells containing only immune spleen
cells served as negative controls, and spleen cells from vacci-
nated mice cultured with 5 µg/ml concanavalin A (Con A)
(Sigma-Aldrich, St Louis, MO, USA) overnight served as a
positive control. The finished plates were air-dried overnight at
room temperature in the dark and sent to ZellNet Consulting
(New York, NY, USA [42]), where the spots were counted
automatically using an ImmunoSpot Series I analyzer (BD Bio-
science, San Diego, CA, USA). If confluence (overlapping
spots) was present in wells, the number of spots in a non-con-
fluent area of that well was determined, and the following
equation was used to estimate the total number of spots in
each well with confluence: total spot number = spot
count+2(spot count × % confluence/ [100% –
%confluence]).
Statistical analysis
Student's t test was performed using Prism 4.0 GraphPad
software (San Diego, CA, USA).
Results
Inhibition of solid tumor growth by vaccination with 
SINCP-neu and Adeno-neu
To determine the effectiveness of vaccination on solid tumor
growth, two groups of 13 mice each were vaccinated once
i.m. in the quadriceps with 100 µg of SINCP-neu or SINCP-
β gal. Two weeks later, the mice were challenged with A2L2
cells injected into the mammary fat pad. Thirty-five days after
the challenge, the mice were killed and if a solid tumor was
present, its mass was determined. All of the mice vaccinated
with SINCP-β gal developed tumors. In the group vaccinated
with SINCP-neu, only six mice developed tumors, and the
mean mass of these six tumors was significantly less than the
mean mass of the tumors in the SINCP-β gal group (0.63 vs
1.02 g; P = 0.0186). When we calculated the mean mass for
all 13 mice in the SINCP-neu group and compared it with the
value of the SINCP-β gal group, the difference was significant
(0.25 vs 1.02 g; P = 0.0001) (Fig. 1a).
Two groups of 10 mice were each vaccinated i.m. in the quad-
riceps once with 1 × 1010 particles of Adeno-neu or Adeno-
empty. Six weeks later, the mice were challenged with A2L2
cells injected into the mammary fat pad. Thirty-five days after
the challenge, the mice were killed and if a solid tumor was
present, its mass was determined. All of the mice vaccinated
with Adeno-empty developed tumors, whereas in the group
vaccinated with Adeno-neu only 1 of 10 mice developed a
tumor (mean mass 1.75 vs 0.2 g; P = 0.0001) (Fig. 1b).
Our findings show that reduced solid tumor growth is attribut-
able to the induction of cellular immunity. This immunity is anti-
gen specific, because it was absent in mice vaccinated with
SINCP-β gal or Adeno-empty, both of which lack the neu gene.
Inhibition of experimental metastasis by vaccination 
with SINCP-neu and Adeno-neu
To determine the effectiveness of vaccination on experimental
metastasis of A2L2 cells, two groups of five mice each were
vaccinated i.m. with 100 µg of SINCP-neu or SINCP-β gal
three times at 2-week intervals. Two weeks after the third vac-
cination, the mice were challenged with A2L2 cells injected
into the tail vein. Twenty-one days after the challenge, the mice
were killed, the lungs removed, and the number of tumor nod-
ules on the surface of the lungs counted with the naked eye.
All of the mice in the SINCP-β gal group had more than 25 sur-
face lung nodules, whereas in the SINCP-neu group all of the
mice had between 1 and 10 nodules (mean number of nodules
105 vs 15; P = 0.0079) (Fig. 2a).
Two groups of nine mice each were vaccinated once with
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A2L2 cells injected into the tail vein. Thirty-five days after the
challenge, the mice were killed, the lungs removed, and the
number of surface lung nodules counted with the naked eye.
All but one mouse in the Adeno-empty group had lung nod-
ules, whereas in the Adeno-neu group five of nine mice had
lung nodules (mean number of nodules 15 vs 1; P = 0.0078)
(Fig. 2b).
Our results show that inhibition of experimental metastasis is
attributable to the induction of cellular immunity. This immunity
is antigen specific because it was absent in mice vaccinated
with SINCP-β gal or Adeno-empty, both of which lack the neu
gene.
neu-Specific IgG in the serum of mice vaccinated with 
SINCP-neu or Adeno-neu
To determine if vaccination induced a humoral immune
response to p185, immediately before tumor challenge 0.1 ml
of blood was collected from the tail vein of each of the mice
treated as described for the experimental metastasis model.
The sera for each group were pooled and analyzed for the
presence of p185-specific IgG by flow cytometry using the
Figure 1
Protection from tumor challenge in the mammary fat pad after vaccina- tion with SINCP or Adeno Protection from tumor challenge in the mammary fat pad after vaccina-
tion with SINCP or Adeno. Groups of mice were vaccinated once with 
SINCP-neu (a plasmid containing Sindbis virus genes and the gene for 
rat HER2/neu) or SINCP-β gal. (a) or with Adeno-neu (an E1,E2a-
deleted adenovirus also containing the gene for rat HER2/neu) or 
Adeno-empty (adenovirus lacking an inserted gene) (b). Two weeks 
after vaccination with SINCP and 6 weeks after vaccination with 
Adeno, the mice were challenged with A2L2 cells injected into a mam-
mary fat pad. Thirty-five days after the tumor challenge, the mice were 
killed and if a solid tumor was present, the mass of the tumor was deter-
mined. Each symbol represents one mouse. Horizontal bars indicate 
means.
Figure 2
Protection from intravenous tumor challenge after vaccination with  SINCP or Adeno Protection from intravenous tumor challenge after vaccination with 
SINCP or Adeno. Groups of mice were vaccinated three times at 2-
week intervals with SINCP-neu (a plasmid containing Sindbis virus 
genes and the gene for rat HER2/neu) or SINCP-β gal. (a) or once with 
Adeno-neu (an E1,E2a-deleted adenovirus also containing the gene for 
rat HER2/neu) or Adeno-empty (adenovirus lacking an inserted gene) 
(b). Two weeks after the final vaccination with SINCP or 6 weeks after 
vaccination with Adeno, the mice were challenged with A2L2 cells 
injected into the tail vein. Twenty-one days after the challenge in 
SINCP-vaccinated animals or 35 days after the challenge in Adeno-vac-
cinated animals, the mice were killed and the number of tumor nodules 
on the surfaces of the lungs was counted. Each symbol represents one 
mouse. Horizontal bars indicate means.Available online http://breast-cancer-research.com/content/7/5/R580
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A2L2 cell line as described previously [29] and in Materials
and methods. Serum from mice vaccinated with SINCP-neu
had a stronger IgG response to A2L2 cells than that from mice
vaccinated with SINCP-β gal (Fig. 3a). Likewise, serum from
mice vaccinated with Adeno-neu  exhibited a stronger IgG
response to A2L2 cells than that from mice vaccinated with
Adeno-empty (Fig. 3b). These results show that the gene vac-
cines induce humoral immunity as well as the cellular immunity
described above.
Therapeutic vaccination with SINCP and Adeno
Because SINCP-neu and Adeno-neu were effective as pre-
ventive vaccines delivered before tumor cell challenge, we
evaluated both vaccines as therapeutic vaccines delivered
after tumor cell challenge. Vaccination conditions were the
same as those described for the experimental metastasis
model. In both the therapeutic mammary fat pad tumor model
and the therapeutic experimental metastasis model, neither
vaccine prolonged the overall survival rate of mice when deliv-
ered after tumor cell challenge (data not shown). Even when
administered as early as 2 days after tumor challenge, neither
vaccine was effective.
Therapeutic vaccination with SINCP and Adeno using a 
prime–boost protocol
To determine whether the therapeutic effectiveness of the vac-
cines could be increased by sequential administration, we
evaluated a prime–boost protocol in which the mice were
primed with a single injection of SINCP 2 days after tumor cell
challenge with A2L2 cells and boosted with injections of
Adeno 9 and 16 days after the challenge. SINCP was always
the prime and Adeno was always the boost, because numer-
ous studies have reported that the most effective protocol is a
plasmid followed by a virus [43-47]. All combinations of
SINCP-neu or SINCP-β gal used as the prime and Adeno-neu
and Adeno-empty used as the boost were tested in both the
therapeutic mammary fat pad tumor model and the therapeutic
experimental metastasis model.
In the therapeutic mammary fat pad tumor model, none of the
combinations significantly increased the overall survival rate
(data not shown). In the therapeutic experimental metastasis
model, only one prime–boost combination was effective: the
overall survival rate was significantly higher when SINCP-neu
was the prime and Adeno-neu was the boost (P = 0.0004)
(Fig. 4a). A comparison of mice vaccinated with SINCP-β gal
as the prime showed that the overall survival rate was slightly
higher when Adeno-neu was the boost than when Adeno-
empty was the boost, but that this increase was not as high
when neu was in both the prime and the boost (Fig. 4b). Thus,
priming with SINCP-neu is essential for the effect, depends on
the presence of the neu gene, and cannot be replaced by non-
specific stimulation with SINCP-β gal.
neu-Specific IgG in the serum of prime–boost-
vaccinated mice
We evaluated the effectiveness of prime–boost vaccination in
an in vitro assay. Naive mice were primed by vaccination with
SINCP-neu and boosted by vaccination twice with Adeno-
neu, or they were primed by vaccination with SINCP-β gal and
boosted by vaccination twice with Adeno-empty [48]. The
presence of the neu gene in both the prime and the boost
resulted in a strong IgG response to the A2L2 cells (Fig. 5a).
The IgG response from vaccination with SINCP-β gal followed
by Adeno-empty (Fig. 5a) was nearly identical to the IgG level
in serum collected from the mice before vaccination (Fig. 5b).
These observations indicated that prime–boost vaccination
produces strong humoral immunity.
Figure 3
Flow cytometric analysis, using A2L2 cells, of serum from mice vacci- nated with SINCP or Adeno Flow cytometric analysis, using A2L2 cells, of serum from mice vacci-
nated with SINCP or Adeno. Serum was collected 2 weeks after the 
third vaccination of mice with SINCP-neu (a plasmid containing Sindbis 
virus genes and the gene for rat HER2/neu) or SINCP-β gal. (a) or 6 
weeks after a single vaccination with Adeno-neu (an E1,E2a-deleted 
adenovirus also containing the gene for rat HER2/neu) or Adeno-empty 
(adenovirus lacking an inserted gene) (b). The immune serum was 
diluted with PBS (1:100), and fluorescein-isothiocyanate-labeled goat 
antimouse IgG diluted in PBS (1:1000) was used as the secondary 
antibody.Breast Cancer Research    Vol 7 No 5    Wang et al.
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Induction of IFNγ -producing cells in the spleens of 
prime–boost-vaccinated mice
To determine whether prime–boost vaccination produced
neu-specific T lymphocytes, we used an IFNγ  ELISPOT assay
to compare spleen cells of mice vaccinated with SINCP-neu
as the prime and Adeno-neu as the boost with spleen cells of
mice vaccinated with SINCP-β gal as the prime and Adeno-
empty as the boost. Spleen cells from vaccinated mice were
co-cultured overnight with A2L2 cells, and the next day the
number of cells producing IFNγ  was determined. Vaccination
with SINCP-neu followed by Adeno-neu resulted in a mean of
more than 150 IFNγ -producing cells per million spleen cells at
all ratios of effector (spleen cell) to stimulator (A2L2 cells)
cells, whereas vaccination with SINCP-β gal followed by
Adeno-empty resulted in a mean of fewer than 20 IFNγ -pro-
ducing cells per million spleen cells (Fig. 6). As a positive con-
trol and possibly as a measure, of a maximum response,
spleen cells were stimulated with 5 µg/ml Con A, which
resulted in a mean that was comparable to the means obtained
with neu in both the prime and the boost. That the presence of
neu in both the prime and the boost resulted in IFNγ  produc-
tion after co-culture with A2L2 cells and that this effect was
not seen with vaccination with SINCP-β gal followed by
Adeno-empty clearly demonstrated that prime–boost vaccina-
tion resulted in antigen-specific induction of cellular immunity.
Discussion
In this report, we showed that vaccination with a plasmid or
adenovirus vaccine containing the gene for neu  protected
mice from challenge with breast cancer cells. In the mammary
fat pad model, a single vaccination with either SINCP-neu or
Adeno-neu was effective. In the experimental lung metastasis
Figure 4
Survival in a therapeutic metastasis model after vaccination with SINCP  (prime) and Adeno (boost) Survival in a therapeutic metastasis model after vaccination with SINCP 
(prime) and Adeno (boost). Mice were given injections into the tail vein 
of A2L2 cells on day 0. On day 2, the mice were vaccinated with either 
SINCP-neu (a plasmid containing Sindbis virus genes and the gene for 
rat HER2/neu) or SINCP-β gal and on days 9 and 16 the mice were 
vaccinated with either Adeno-neu (an E1,E2a-deleted adenovirus also 
containing the gene for rat HER2/neu) or Adeno-empty (adenovirus 
lacking an inserted gene). (a) Overall survival of mice vaccinated with 
SINCP-neu and Adeno-neu compared with mice vaccinated with 
SINCP-β gal and Adeno-empty. (b) Overall survival of mice vaccinated 
with SINCP-neu and Adeno-neu compared with mice vaccinated with 
SINCP-β gal and Adeno-neu. P values were determined by a log-rank 
test of Kaplan–Meier survival curves.
Figure 5
Flow cytometric analysis using A2L2 cells of serum from mice vacci- nated with SINCP and Adeno Flow cytometric analysis using A2L2 cells of serum from mice vacci-
nated with SINCP and Adeno. Naive mice were vaccinated with 
SINCP-neu (a plasmid containing Sindbis virus genes and the gene for 
rat HER2/neu) as the prime and twice, at 2-week intervals, with Adeno-
neu (an E1,E2a-deleted adenovirus also containing the gene for rat 
HER2/neu) as the boost; or they were vaccinated with SINCP-β gal as 
the prime and then twice, at 2-week intervals, with Adeno-empty (aden-
ovirus lacking an inserted gene) as the boost. (a) Immune serum col-
lected 2 weeks after the second Adeno vaccination was diluted 1:100 
and analyzed by flow cytometry. (b) A2L2 cells treated with fluorescein-
isothiocyanate-labeled goat antimouse IgG (secondary antibody) and 
serum collected before vaccination (prebleed) served as the negative 
controls, and A2L2 cells treated with a commercial polyclonal antibody 
against p185 served as the positive control.Available online http://breast-cancer-research.com/content/7/5/R580
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model, a single vaccination with Adeno-neu was effective, and
the SINCP-neu vaccine was effective when delivered three
times at 2-week intervals.
In our study, serum from mice vaccinated with SINCP-neu or
Adeno-neu  contained high levels of IgG that reacted with
A2L2 cells, whereas serum from mice vaccinated with SINCP-
β gal or Adeno-empty was at background levels. We previously
showed that immune serum from gene-vaccinated mice does
not react with the parental cell line (66.3) that was transfected
with the neu gene to create A2L2 [29]. The level of immuno-
flourescence resulting from a single vaccination with Adeno-
neu was one log greater than that resulting from three vacci-
nations with SINCP-neu. Taken together with the results
described in the previous paragraph for the experimental
metastasis model, this finding indicates that at these doses
and this schedule, Adeno-neu is the more immunogenic vac-
cine. Of course, there is no way to accurately compare a plas-
mid vaccine with a viral vaccine except in relative terms.
Although both SINCP-neu and Adeno-neu produced robust
protection in two tumor-prevention models, both gene vac-
cines were ineffective when used after A2L2 cells were
injected into the mammary fat pad or i.v., even when vaccina-
tion was begun only 2 days after tumor cell injection and vac-
cination was repeated three times for SINCP-neu. Adeno-neu
was injected only once in these therapeutic models. Because
many publications have described the effectiveness of prime–
boost vaccination in which the prime is a plasmid gene vaccine
and the boost is a viral gene vaccine, and have shown that
priming with a plasmid and boosting with a virus is more effec-
tive than the opposite [43,44,47], we tested this strategy in
our two therapeutic tumor models.
In our experimental metastasis model, priming with SINCP-
neu followed by boosting twice with Adeno-neu prolonged the
lives of mice compared with prime–boost vaccination with
SINCP-β gal and Adeno-empty. This effect was seen only in
the experimental metastasis model and not in the experimental
mammary fat pad model, and no other prime–boost combina-
tion worked. Although this combination of SINCP-neu  and
Adeno-neu  was able to increase the survival rate, all mice
eventually succumbed to tumor growth and were killed
because of moribundity. We also found that prime–boost vac-
cination results in antigen-specific induction of both cellular
and humoral immunity. A question that cannot be answered by
our findings is the relative role of cellular immunity versus
humoral immunity in the in vitro antitumor effect.
With the mandate to move promising laboratory findings to the
clinic, it is most important to evaluate the implications of these
findings with regard to treatment of patients. A gene vaccine
against HER2/neu  could be effective for patients with a
HER2/neu-expressing tumor but could not be rationally used
to manage a HER2/neu-negative tumor. Many types of HER2/
neu-expressing tumors are noteworthy for their aggressive
growth and high metastatic potential [50]. Our data indicate
that combined vaccination in a prime–boost schedule may be
the most likely to produce a clinical effect. However, these
vaccines require phase I toxicity testing individually before they
could be evaluated in a prime–boost protocol. A phase I/II
study may yield valuable information regarding increased sur-
vival rates and induction of cellular and humoral immunity as
measured by in vitro assays. Testing of either SINCP-neu or
Adeno-neu in patients will require the production of clinical-
grade material, which could be less of a hurdle for a plasmid
than for a virus. Nonetheless, our data identify two promising
gene vaccines against HER2/neu, an antigen associated with
aggressive tumor growth and metastasis.
Conclusion
We demonstrated that in mice, vaccination with a plasmid
gene vaccine and an adenovirus gene vaccine, each contain-
ing the gene for HER2/neu, prevented growth of a HER2/neu-
expressing breast cancer cell line injected into the mammary
fat pad or i.v. The gene vaccines were not effective individually
Figure 6
IFNγ  ELISPOT analysis of spleen cells from mice vaccinated with SINCP (prime) and Adeno (boost) IFNγ  ELISPOT analysis of spleen cells from mice vaccinated with SINCP (prime) and Adeno (boost). Naive mice were vaccinated with SINCP-neu (a 
plasmid containing Sindbis virus genes and the gene for rat HER2/neu) and then twice, at 2-week intervals, with Adeno-neu (an E1,E2a-deleted 
adenovirus also containing the gene for rat HER2/neu). Spleen cells were collected 2 weeks after the second Adeno vaccination and were cultured 
overnight with 5 µg/ml concanavalin A, without stimulation, or with A2L2 cells at three different effector:stimulator ratios. The number of IFNγ -secret-
ing cells was determined using a commercial ELISPOT procedure and antibody pair. Horizontal bars indicate means. IFNγ , interferon γ .Breast Cancer Research    Vol 7 No 5    Wang et al.
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in therapeutic vaccine models in which vaccination took place
after tumor cells were injected. However, sequential adminis-
tration of the vaccines in a prime–boost protocol was
therapeutically effective when the tumor cells were injected i.v.
The vaccines induced high levels of both cellular and humoral
immunity as determined by in vitro assessment. Clinical evalu-
ation of these vaccines, particularly when used sequentially, is
justified.
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